MIT Engineers Deploy Machine Learning to Design Heat-Resistant RNA Vaccines
Engineers at the Massachusetts Institute of Technology have deployed a data-efficient machine-learning algorithm to reformulate lipid nanoparticles used in mRNA vaccine delivery, enabling formulations to withstand room temperature for up to a year or 98 degrees Fahrenheit for two months. The breakthrough addresses a primary logistical barrier for RNA immunizations, which traditionally require strict ultracold storage between minus 20 and minus 80 degrees Celsius.
According to MIT News, prior Koch Institute research successfully demonstrated polymer-stabilized microneedle vaccine printing in 2023, but adapting these techniques to commercial LNPs stalled until machine-learning optimization was introduced. According to Nature Biotechnology, mIT researchers published their breakthrough on data-efficient AI for heat-stable mRNA-LNP vaccines in Nature Biotechnology on September 28, 2026 (DOI: 10.1038/s41587-026-03331-w).
Published in Nature Biotechnology, the research was led by investigators in MIT's Koch Institute for Integrative Cancer Research and the Computer Science and Artificial Intelligence Laboratory. The methodology bypasses the exhaustive physical screening that previously stalled laboratory teams, demonstrating how specialized algorithms can accelerate biological formulation discovery using minimal experimental inputs.
Overcoming Formulation Bottlenecks with Small Data
Lipid nanoparticles shield fragile messenger RNA molecules from enzymatic degradation and facilitate cellular entry. According to MIT News, however, adapting FDA-approved LNP compositions used in commercial COVID-19 vaccines to withstand elevated heat proved difficult through conventional trial-and-error screening. Researchers reported hitting persistent roadblocks while testing various excipient combinations.
To break the deadlock, the team collaborated with MIT CSAIL researchers to deploy a machine-learning algorithm capable of converging on optimal solutions from small datasets. Mina Konaković Luković, an assistant professor of electrical engineering and computer science at CSAIL, noted that the model reached stable formulations within a handful of iterations instead of requiring exhaustive physical searches.
Screening Excipients and Predicting Ratios
According to MIT News, the algorithm analyzed nearly 50 FDA-approved excipients, including sugars, salts, and polymers. Investigators measured protective efficacy by tracking the expression of firefly luciferase reporter proteins delivered into cells via lipid nanoparticles.
From these trials, the team selected five promising excipients and directed the algorithm to predict optimal mixing ratios modeled on Moderna-type formulations. Iterative testing cycles spanning just a few weeks yielded a viable candidate formulation, drastically shortening a timeline that previously consumed months without achieving complete thermal stability.
Animal Trials and Solid-State Microneedle Delivery
Vascular drying was used to convert the newly formulated mRNA-antigen particles into solid states. When administered to mice after prolonged high-temperature storage, the vaccines stimulated immune responses comparable to fresh formulations based on conventional Moderna-style delivery systems.
According to MIT News, for Massachusetts Institute of Technology, The optimization methodology successfully adapted both Moderna-type and Pfizer-BioNTech-type LNP formulations, with investigators planning commercial microfluidic scale-up and clinical trials. According to MIT News, solid-state microneedle patches maintained mRNA payload integrity after two months of storage at 37°C (98°F), eliciting immune responses equivalent to fresh liquid vaccines in animal trials.
The thermal stability also enabled the successful creation of solid microneedle patches designed to dissolve upon skin application. According to MIT News, tests confirmed that these patches delivered SARS-CoV-2 antigens effectively, eliciting robust immune protection without requiring standard liquid injection infrastructure.
Broad Platform Applicability and Next Steps
Beyond Moderna-style architectures, the research team demonstrated that the algorithm could optimize formulations corresponding to Pfizer-BioNTech nanoparticle designs by adjusting component ratios. The flexibility suggests that once optimized, heat-tolerant LNP bases could accommodate diverse mRNA payloads across various therapeutic applications, including emerging cancer vaccines.
Funding for the research was provided in part by the Gates Foundation. Investigators plan to advance the technology toward manufacturing scale and human clinical evaluations to determine performance consistency outside laboratory environments.
According to MIT News, the Gates Foundation provided grant funding for the study to develop thermostable vaccine delivery platforms targeting low- and middle-income countries. According to MIT News, for mRNA vaccines, The algorithm optimized formulations using commodity FDA-approved excipients produced at commercial scale for pennies per gram, eliminating cold-chain logistics that represent 20% to 30% of vaccine distribution costs.